PrEP use high but wanes after three months among young African women

(NIH/National Institute of Allergy and Infectious Diseases) In a study of open-label Truvada as daily pre-exposure prophylaxis (PrEP) to prevent HIV among young African women and adolescent girls, 95% initiated PrEP, and most used PrEP for the first three months. However, PrEP use fell in this critical population during a year of follow-up clinic visits, although HIV incidence at 12 months was low. The preliminary results suggest that tailored strategies may be needed to engage young African women in consistent PrEP use.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news